Table 2.
Cardiac magnetic resonance imaging analysis 4+1 days post percutaneous coronary intervention.
| Characteristic |
Overall (N = 40) |
Shenfu injection (n = 20) |
Placebo (n = 20) |
P-value |
|---|---|---|---|---|
| CMR performed | 32 (80.0) | 16 (80.0) | 16 (80.0) | 1.0 |
| CMR analyzed | 32 (80.0) | 16 (80.0) | 16 (80.0) | 1.0 |
| CMR time from PCI, median (IQR), days | 4 (4–5) | 4 (4–5) | 4 (4–5) | 0.70 |
| Infarct sizea, median (IQR), % | 26.0 (20.4–31.5) | 23.9 (15.2–28.5) | 27.0 (21.9–31.9) | 0.42 |
| LV mass, median (IQR), g | 144.0 (124.0–182.5) | 152.9 (131.2–177.4) | 137.6 (120.2–189.6) | 0.56 |
| Area at risk (edema mass)a, median (IQR), % | 41.7 (27.0–50.3) | 39.9 (26.7–47.9) | 47.9 (29.8–56.2) | 0.36 |
| Myocardial salvage index, median (IQR), % | 41.9 (20.9–54.4) | 40.4 (12.9–63.2) | 41.9 (34.8–45.3) | 0.98 |
| MVO prevalence, % | 24/32 (75.0) | 12/16 (75.0) | 12/16 (75.0) | 1.0 |
| MVO massa, median (IQR), % | 1.77 (0.01–3.02) | 1.90 (0.01–3.11) | 1.33 (0.07–2.96) | 0.86 |
| IMH prevalence, % | 17/32 (53.1) | 10/16 (62.5) | 7/16 (43.8) | 0.29 |
| IMH massa, median (IQR), % | 0.31 (0.00–3.17) | 1.08 (0.00–3.37) | 0.00 (0.00–2.80) | 0.45 |
| LVEDV, mean (SD), ml | 88.9 (27.4) | 94.8 (27.5) | 82.9 (26.8) | 0.23 |
| LVESV, mean (SD), ml | 46.7 (23.0) | 50.5 (23.8) | 42.9 (22.3) | 0.36 |
| LVEF, mean (SD), % | 49.6 (12.3) | 48.7 (12.4) | 50.5 (12.5) | 0.69 |
CMR, cardiac magnetic resonance; IMH, intramyocardial hemorrhage; IQR, interquartile range; LV, left ventricular; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; MVO, microvascular obstruction; PCI, percutaneous coronary intervention; SD, standard deviation; TIMI, Thrombolysis In Myocardial Infarction. Data are presented as mean (SD), median (IQR), n (%), or n/N (%).
a
Expressed as a percentage of LV mass.